Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390032 | 0.99 | POLB (0.55) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| Ammonia Solution, Strong SCHEMBL5449039 | 0.99 | POLB (0.55) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL29022580 | 0.99 | POLB (0.55) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL5449043 | 0.88 | MAPT (0.45) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL28753724 | 0.84 | GAA (0.48) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL17817254 | 0.82 | POLB (0.48) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL6720846 | 0.79 | POLB (0.48) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL28753721 | 0.79 | POLB (0.57) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL14429924 | 0.76 | MAPT (0.48) | POLBMEN1KMT2AL3MBTL1RXFP1 | |
| SCHEMBL14429913 | 0.76 | MAPT (0.48) | POLBMEN1KMT2AL3MBTL1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119114152-A | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-12-13 | — | — | CN | disclosed |
| CN-118695780-A | Composition and method for producing the same | 阿斯制药株式会社 | 2024-09-24 | — | — | CN | disclosed |
| CN-110769931-B | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-09-17 | — | — | CN | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-117281115-A | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2023-12-26 | — | — | CN | disclosed |
| EP-4230042-A1 | ANTIPATHOGENIC DRUG, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN PROCESSING DEVICE, METHOD FOR PRODUCING ANTIPATHOGENIC DRUG, ANTIBACTERIAL METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN PROCESSING METHOD | Acenet Inc. (JP) | 2023-08-23 | — | — | EP | disclosed |
| CN-116322332-A | Antipathogenic agent, antibacterial agent, antiviral agent, pathogen treatment device, method for producing antipathogenic agent, antibacterial method, virus inactivation method, and pathogen treatment method | 株式会社ACENET | 2023-06-23 | — | — | CN | disclosed |
| CN-116157109-A | Oral pharmaceutical preparation | 国立大学法人大阪大学 | 2023-05-23 | — | — | CN | disclosed |
| EP-4147703-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022075451-A1 | ANTIPATHOGENIC DRUG, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN PROCESSING DEVICE, METHOD FOR PRODUCING ANTIPATHOGENIC DRUG, ANTIBACTERIAL METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN PROCESSING METHOD | 株式会社エースネット | 2022-04-14 | — | — | WO | disclosed |
| US-11077095-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077095-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | POLB 2079/4885MEN1 4000/4885KMT2A 3467/4885 |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | POLB 2079/4885MEN1 4000/4885KMT2A 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.